Zai Lab Ltd
ZLAB
View Detailed Chart
22.144USD
+0.254+1.16%
Market hours （ET）Quotes delayed by 15 min
2.45BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.16%
5 Days
-17.22%
1 Month
-26.77%
6 Months
-24.27%
Year to Date
-15.45%
1 Year
-27.68%
View Detailed Chart
TradingKey Stock Score of Zai Lab Ltd
Currency: USD Updated: 2025-11-10Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zai Lab Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
50.734
Target Price
+131.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zai Lab Ltd Highlights
StrengthsRisks
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 85.54% year-on-year.
Undervalued
The company’s latest PE is -11.23, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.61M shares, decreasing 24.80% quarter-over-quarter.
Held by Ron Baron
Star Investor Ron Baron holds 1.59M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.
Zai Lab Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Zai Lab Ltd Info
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Ticker SymbolZLAB
CompanyZai Lab Ltd
CEODr. Ying (Samantha) Du, Ph.D.
Websitehttps://www.zailaboratory.com/
Related Instruments
+2.69%
+2.11%
+2.29%
+1.67%
+2.57%
+4.07%
+3.50%
+6.74%
+3.05%
+3.10%
+2.62%
+1.18%
-0.27%
+1.89%
+2.19%
+3.29%
0.00%
+2.03%
+2.47%
+2.25%Popular Symbols
